Clay and non-clay minerals in the pharmaceutical industry
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Therapeutic Uses of Natural Elements · Clay minerals and soil interactions · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (78)
Show source-provided references
1. Sol–gel transitions of sodium montmorillonite dispersions10.1016/S0169-1317(99)00040-X ↗
2. Use of clays as drug delivery systems: possibilities and limitations10.1016/j.clay.2006.06.015 ↗
3. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate10.1016/S0939-6411(98)00029-0 ↗
4. Sepiolite: properties and uses
5. Erythromycin–antacid interaction
6. Industrial minerals in pharmaceuticals
7. Zn2+-exchanged clinoptilolite-rich rock as active carrier for antibiotics in anti-acne topical therapy: in-vitro characterization and preliminary formulation studies10.1016/j.clay.2006.04.014 ↗
8. The bentonites in pelotherapy: thermal properties of clay pastes from Sardinia (Italy)10.1016/S0169-1317(99)00050-2 ↗
9. Clay minerals and their beneficial effects upon human health. A review10.1016/S0169-1317(01)00085-0 ↗
10. Carretero · 2007
11. Clays and human health
12. Zeolites in biomedical application: Zn-exchanged clinoptilolite-rich rock as active carrier for antibiotics in anti-acne topical therapy10.1016/j.clay.2004.04.004 ↗
13. Clinical application of injectable calcium sulfate on early bone consolidation in distraction osteogenesis for the treatment of craniofacial microsomia10.1097/00001665-200205000-00019 ↗
14. Clay minerals and layered double hydroxides for novel biological applications10.1016/j.clay.2006.07.007 ↗
15. Las arcillas en formulaciones farmacéuticas
16. Role of ferric iron in the oxidation of hydrocortisone by sepiolite and palygorskite10.1346/CCMN.1983.0310204 ↗
17. Layered double hydroxides and human health: an overview10.1016/j.clay.2006.06.010 ↗
18. Application of phenyl salycilate-sepiolite systems as ultraviolet radiation filters10.1180/claymin.1998.033.3.09 ↗
19. Clays and clay minerals as drugs
20. The behaviour of the sodium salt of indomethacin in the cores of film-coated granules containing various fillers10.1016/0378-5173(91)90391-Z ↗
21. Viscosity of some clay-based coating colors at high shear rates10.1007/BF01339890 ↗
22. Thermal properties of clay pastes for pelotherapy10.1016/0169-1317(91)90008-W ↗
23. Effects of fibrous clay minerals on dexamethasone stability
24. Interaction of dexamethasone and montmorillonite. Adsorption–degradation process10.1016/0169-1317(89)90021-5 ↗
25. Minerales utilizados en la industria farmaceútica
26. Grim · 1962
27. Grim · 1968
28. 1993 · vol. 28
29. 1992 · vol. 4
30. Effect of some excipients on the dissolution of phenytoin and acetazolamide from capsule formulations
31. Adsorption of paracetamol and chloroquine phosphate by some antacids10.1111/j.2042-7158.1992.tb05488.x ↗
32. Interaction of diazepam with excipients in binary powder form
33. Interaction study of diazepam with excipients in liquid and solid state
34. Effect of relative humidity on the photocatalytic activity of titanium dioxide and photostability of famotidine10.1002/jps.10575 ↗
35. The in vitro adsorption of some antibiotics on antacids
36. Klein · 1993
37. Ingredients of flow of kaolin and bentonite dispersions10.1016/0169-1317(89)90003-3 ↗
38. Colloid clay science
39. Chemical stability of acetylsalicylic acid in tablets prepared with different commercial brands of dicalcium phosphate dihydrate10.1016/0378-5173(94)90442-1 ↗
40. Les minéraux en pharmacie
41. Comparative study of the cooling rates of bentonite, sepiolite and common clays for their use in pelotherapy10.1016/j.clay.2006.06.014 ↗
42. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier10.1016/S0142-9612(01)00325-8 ↗
43. Pharmaceutical and cosmetic applications of clays
44. Compositional, technical and safety specifications of clays to be used as pharmaceutical and cosmetic products10.1016/j.clay.2006.06.016 ↗
45. Mineral makeover
46. The colloidal and rheological properties of bentonite suspensions10.1016/S0001-8686(99)00005-6 ↗
47. Colloidal behaviour of montmorillonite in presence of Fe3+ ions10.1016/S0927-7757(99)00032-1 ↗
48. The swelling behaviour of clays10.1016/0169-1317(89)90005-7 ↗
49. The effect of added salts on solubilization by a non-ionic surfactant10.1111/j.2042-7158.1981.tb13698.x ↗
50. Sustained-release applications of montmorillonite interaction with amphetamine sulfate10.1002/jps.2600660115 ↗
51. Thixotropy: a special review10.1016/0377-0257(79)87001-9 ↗
52. The shearing behaviour of clays10.1016/0169-1317(89)90004-5 ↗
53. The effect of phenol on the electrolyte flocculation of certain polymeric dispersions to thixotropic gels10.1023/A:1018930709603 ↗
54. The effect of excipients on the stability of levothroxine sodium pentahydrate tablets10.1016/S0378-5173(03)00387-9 ↗
55. Characterization of antacid compounds containing both aluminum and magnesium. II. Codried powders10.1023/A:1018910705853 ↗
56. Mechanism of adsorption of clyndamicine and tetracycline by montmorillonite10.1002/jps.2600670815 ↗
57. Interaction of digoxin and montmorillonite: mechanism of adsorption and degradation10.1002/jps.2600680327 ↗
58. Formulation of controlled release drug preparations with antacid effect
59. Interaction of antacids with anti-arrhythmics. Part 5. Effect of aluminum hydroxide and magnesium oxide on the bioavailability of quinidine, procainamide, and propranolol in dogs
60. Problems with the hydroxyapatite orbital implant: experience with 250 consecutive cases10.1136/bjo.78.9.702 ↗
61. Gelling properties of sepiolite versus montmorillonite10.1016/0169-1317(88)90016-6 ↗
62. Adsorption of atropine sulfate and hyoscyamine hydrobromide by various antacids
63. Toxic metals in the environment: the role of surfaces10.2113/gselements.1.4.193 ↗
64. Manufacturing method of stable enteric granules of a new antiulcer drug (lansoprazole)10.3109/03639049409050206 ↗
65. Solid–state interaction of magnesium oxide and ibuprofen to form a salt10.1023/A:1015983732667 ↗
66. Ultrastructure and flow behavior of colloidal smectite dispersions10.1016/0021-9797(88)90122-1 ↗
67. van Olphen · 1977
68. Clay science: facts and perspectives. In: Proceedings of the Mediterranean Clay Meeting, Lipari 27–30 September 1992
69. Argille curative. Antefatti, fatti e misfatti
70. Applicazioni e utilizzazioni medico-sanitarie di materiali argillosi (naturali e modificati)
71. Formulation of muds for pelotherapy: effects of “maduration” by different mineral waters10.1016/j.clay.2003.10.002 ↗
72. Thermal muds: perspectives of innovations10.1016/j.clay.2006.04.013 ↗
73. Pharmaceutical grade phyllosilicate dispersions: the influence of shear history on floc structure10.1016/S0378-5173(99)00075-7 ↗
74. Uses of clay minerals in semisolid health care and therapeutic products10.1016/j.clay.2006.07.006 ↗
75. Clay minerals and health
76. Weiner · 1989
77. The importance of crystal morphology on the viscosity of concentrated suspensions of kaolin10.1016/S0169-1317(97)00006-9 ↗
78. Suppression of agglomeration in fluidized bed coating I. Suppression of agglomeration by adding sodium chloride10.1016/S0378-5173(97)00259-7 ↗